Get started
Author

Fang Xie

Observed names: F Xie, F. Xie, Fenglong Xie, Xie, F.
ORCID: 0000-0002-3429-4647
Observed ORCID: 0000-0002-3429-4647
OpenAlex ID: A5003597237
The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents
2011 · Jeffrey R Curtis, Fenglong Xie, et al. · Annals of the Rheumatic Diseases · 114
Comparative safety of flavocoxid vs prescription NSAIDs among osteoarthritis patients
2020 · J.R. Curtis, J.K. Owensby, et al. · Osteoarthritis and Cartilage · 8
PDF
Pgi26 Canadian Cost-utility Analysis of Initiation and Maintenance Treatment With Anti-tnf Drugs for Refractory Crohn's Disease
2010 · G Blackhouse, F Xie, et al. · Value in Health · 6
PDF
Abs1031 Baseline Features and Outcomes Among Patients With Granulomatosis With Polyangiitis or Microscopic Polyangiitis on Avacopan in a Community Practice-based Research Network in the U.s.
2025 · B. Jaros, E. Holladay, et al. · Annals of the Rheumatic Diseases · 1
Abs0730 Treatment Sequencing and Line of Therapy for Biologics and Jak Inhibitors in Rheumatoid Arthritis Patients: Implications for Design and Uptake of New Drugs and Diagnostics
2025 · J.R. Curtis, S. Daigle, et al. · Annals of the Rheumatic Diseases
Ab1447 Immune Related Adverse Events Due to Checkpoint Inhibitor Therapy in Cancer Patients With Rheumatoid Arthritis: a Medicare Claims Study
2024 · D. Jannat-Khah, F. Xie, et al. · Annals of the Rheumatic Diseases
FRI0531 Biologic and dmard combination and monotherapy among medicare beneficiaries with rheumatoid arthritis
2013 · J.R. Curtis, J. Zhang, et al. · Annals of the Rheumatic Diseases
Works count: 9
Citation count: 129
H-index: 3
I10-index: 1
Year
Topic
Type